Home › NCT04087629

StrataCTX® as a Steroid Sparing Device

Post-marketing Surveillance of StrataCTX® Flexible Wound Dressing for Use as a Steroid Sparing Agent

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age ≥ 18 years
* Ability to sign informed consent document
* Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel
* Patients with a diagnosis of CTCL who have intractable pruritis
* Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief
* Patients on chemo/immunotherapy with drug induced rash

Exclusion Criteria:

* Patients currently undergoing radiotherapy
* Patients currently receiving oral steroids
* Patients who are unable to apply topical medications

About the study

The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.

What is being tested

• StrataCTX® gel (device)

Sponsor: Columbia University · Participants: 70 · Started: Jul 7, 2021

Contact the study team

• Larisa Geskin, MD · Phone: 212-305-5293

Official record on ClinicalTrials.gov — NCT04087629

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.